
Paul Sax
@paulsaxmd
Harvard/Brigham Infectious Diseases doctor, writer, @CIDJournal editor, educator. Prefer baseball to football, pizza to sushi, dogs to cats, Beatles to Stones.
ID: 30761456
http://blogs.jwatch.org/hiv-id-observations/ 13-04-2009 00:36:46
5,5K Tweet
57,57K Followers
1,1K Following

I know youāve all been on tenterhooks, awaiting the dramatic conclusion to āHow PCP Became PJPā. Well here it is. Youāll laugh! Youāll cry! And youāll finish reading it so much better informed about this critical debate. NEJM Journal Watch NEJM blogs.jwatch.org/hiv-id-observaā¦

In the aftermath of the election results, I thought of this really interesting piece from 2022, written anonymously. There's a lot here that's worth reading for us ID docs, whether we agree or not. #IDTwitter Vinay Prasad MD MPH drvinayprasad.com/p/why-no-one-wā¦

So grateful for the invitation to join your impressive ID division for a couple of days! Thank you! Great to reconnect with Josh Barocas, MD*, spend time on a snowy drive with @EPoeschla, and chat with many faculty and fellows. (* MGB Infectious Diseases Fellowship grad.)

Hi folks, have always loved this Allman Brothers Band song, which seems appropriate to post on this fine clear day. C'mon over to paulsaxmd.bsky.social youtu.be/JSMubgZoL58?siā¦


The communications pause for federal health agencies meant that the CDC couldn't publish MMWR last week -- first time in the publication's 60+ year history this has happened. Not happyā¹ļø-- MMWR is a vital communication tool about infectious threats. blogs.jwatch.org/hiv-id-observaā¦





Latest post on a new antibiotic, gepotidacin, which has a novel mechanism of action, is the first new drug for uncomplicated UTIs in decades, and has a brand name that sounds a lot like a tropical bird. Plus some digressions on prog rock, for no reason. blogs.jwatch.org/hiv-id-observaā¦


The SNAP trial may finally resolve some of the longest-running debates in SAB management (cefazolin vs semi-synthetic PCN? Is PCN really active vs PSSA?). Congrats to Steven Tong Joshua Davis, and the global team who made this ambitious trial happen. blogs.jwatch.org/hiv-id-observaā¦


The new head of FDAās CBER, Vinay Prasad MD MPH, is undoubtedly brilliant. He'll oversee vaccines, gene Rx, monoclonal Abs, & blood products. Let's hope he can get along well enough with others to be an effective leader -- the stakes are pretty darn high! blogs.jwatch.org/hiv-id-observaā¦

We love what we do. But yes, weād also like to get paid. ID is a cognitive, consult-heavy specialty -- and often a āloss leaderā in a fee-for-service world. A look at how the money actually flows (or doesnāt), Part 1. h/t ron nahass Brad Spellberg š blogs.jwatch.org/hiv-id-observaā¦

Latest FDA actions on Covid vaccines: 1. Novavax approved: š 2. Narrowed indications for all vaccines: ā/ā 3. Called for more clinical trials:š Thoughts about what this might mean -- and 100% agree we need updated data to inform clinical practice. blogs.jwatch.org/hiv-id-observaā¦



The head of HHS said heād preserve ACIP. Then he fired the entire committee. Now a new panel--with mostly unclear expertise in clinical trials, vaccines, and ID--is in place. Time for high alert for changes that could seriously affect public health. blogs.jwatch.org/hiv-id-observaā¦